Emerging treatment options for short bowel syndrome: potential role of teduglutide
Cheng T Tee1,2 Katharina Wallis1,3 Simon M Gabe1,41Lennard-Jones Intestinal Failure Unit, St Mark's Hospital and Academic Institute, Harrow, UK; 2Antigen Presentation Research Group, Imperial College London, Northwick Park and St Mark's Campus, Harrow, UK; 3West Hertfordshire...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2011-08-01
|
| Series: | Clinical and Experimental Gastroenterology |
| Online Access: | http://www.dovepress.com/emerging-treatment-options-for-short-bowel-syndrome-potential-role-of--a8109 |
| _version_ | 1811314918824083456 |
|---|---|
| author | Gabe SM Wallis K Tee CT |
| author_facet | Gabe SM Wallis K Tee CT |
| author_sort | Gabe SM |
| collection | DOAJ |
| description | Cheng T Tee1,2 Katharina Wallis1,3 Simon M Gabe1,41Lennard-Jones Intestinal Failure Unit, St Mark's Hospital and Academic Institute, Harrow, UK; 2Antigen Presentation Research Group, Imperial College London, Northwick Park and St Mark's Campus, Harrow, UK; 3West Hertfordshire Hospitals NHS Trust, Watford, UK; 4Division of Surgery, Oncology, Reproductive Biology and Anaesthetics, Imperial College Healthcare, London, UKIntroduction: Current medical management of short bowel syndrome (SBS) involves the use of lifelong parenteral nutrition (PN). Glucagon-like peptide-2 (GLP-2), an important intestinotrophic growth factor has been shown to increase intestinal absorption in SBS through augmentation of post-resection intestinal adaptation. This may lead to the reduction of PN dependence in patients with SBS.Areas covered in review: Advancing research of GLP-2 physiology has spurred the growing understanding of the diverse effects of GLP-2. The development of the degradation resistant GLP-2 analog, teduglutide (GattexTM, NPS Pharmaceuticals, Bedminster, NJ), has allowed its exploration as a therapeutic agent in a variety of clinical settings. Recent multicenter, placebo-controlled studies of GLP-2 in SBS patients demonstrate meaningful reductions in PN requirements with good safety profiles. The reparative and immunomodulatory effects of teduglutide may also be beneficial in patients with inflammatory bowel disease (IBD). Safety concerns about possible carcinogenic properties during long-term use require ongoing evaluation.Summary: GLP-2 appears to offer a novel adjuvant treatment modality for SBS. Promise for its use in other clinical settings like IBD has been shown in small pilot studies.Keywords: glucagon-like peptide-2, intestinal failure, intestinal adaptation, parenteral nutrition |
| first_indexed | 2024-04-13T11:21:01Z |
| format | Article |
| id | doaj.art-5e771cdb2c5f44d9a325c51524bc8568 |
| institution | Directory Open Access Journal |
| issn | 1178-7023 |
| language | English |
| last_indexed | 2024-04-13T11:21:01Z |
| publishDate | 2011-08-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical and Experimental Gastroenterology |
| spelling | doaj.art-5e771cdb2c5f44d9a325c51524bc85682022-12-22T02:48:49ZengDove Medical PressClinical and Experimental Gastroenterology1178-70232011-08-012011default189196Emerging treatment options for short bowel syndrome: potential role of teduglutideGabe SMWallis KTee CTCheng T Tee1,2 Katharina Wallis1,3 Simon M Gabe1,41Lennard-Jones Intestinal Failure Unit, St Mark's Hospital and Academic Institute, Harrow, UK; 2Antigen Presentation Research Group, Imperial College London, Northwick Park and St Mark's Campus, Harrow, UK; 3West Hertfordshire Hospitals NHS Trust, Watford, UK; 4Division of Surgery, Oncology, Reproductive Biology and Anaesthetics, Imperial College Healthcare, London, UKIntroduction: Current medical management of short bowel syndrome (SBS) involves the use of lifelong parenteral nutrition (PN). Glucagon-like peptide-2 (GLP-2), an important intestinotrophic growth factor has been shown to increase intestinal absorption in SBS through augmentation of post-resection intestinal adaptation. This may lead to the reduction of PN dependence in patients with SBS.Areas covered in review: Advancing research of GLP-2 physiology has spurred the growing understanding of the diverse effects of GLP-2. The development of the degradation resistant GLP-2 analog, teduglutide (GattexTM, NPS Pharmaceuticals, Bedminster, NJ), has allowed its exploration as a therapeutic agent in a variety of clinical settings. Recent multicenter, placebo-controlled studies of GLP-2 in SBS patients demonstrate meaningful reductions in PN requirements with good safety profiles. The reparative and immunomodulatory effects of teduglutide may also be beneficial in patients with inflammatory bowel disease (IBD). Safety concerns about possible carcinogenic properties during long-term use require ongoing evaluation.Summary: GLP-2 appears to offer a novel adjuvant treatment modality for SBS. Promise for its use in other clinical settings like IBD has been shown in small pilot studies.Keywords: glucagon-like peptide-2, intestinal failure, intestinal adaptation, parenteral nutritionhttp://www.dovepress.com/emerging-treatment-options-for-short-bowel-syndrome-potential-role-of--a8109 |
| spellingShingle | Gabe SM Wallis K Tee CT Emerging treatment options for short bowel syndrome: potential role of teduglutide Clinical and Experimental Gastroenterology |
| title | Emerging treatment options for short bowel syndrome: potential role of teduglutide |
| title_full | Emerging treatment options for short bowel syndrome: potential role of teduglutide |
| title_fullStr | Emerging treatment options for short bowel syndrome: potential role of teduglutide |
| title_full_unstemmed | Emerging treatment options for short bowel syndrome: potential role of teduglutide |
| title_short | Emerging treatment options for short bowel syndrome: potential role of teduglutide |
| title_sort | emerging treatment options for short bowel syndrome potential role of teduglutide |
| url | http://www.dovepress.com/emerging-treatment-options-for-short-bowel-syndrome-potential-role-of--a8109 |
| work_keys_str_mv | AT gabesm emergingtreatmentoptionsforshortbowelsyndromepotentialroleofteduglutide AT wallisk emergingtreatmentoptionsforshortbowelsyndromepotentialroleofteduglutide AT teect emergingtreatmentoptionsforshortbowelsyndromepotentialroleofteduglutide |